Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals

Paul E Gray¹,², Adam W Bartlett¹,² & Stuart G Tangye³,⁴

¹Department of Immunology and Infectious Diseases, Sydney Children’s Hospital, Randwick, NSW, Australia
²School of Women’s and Children’s Health, University of New South Wales, Randwick, NSW, Australia
³Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
⁴St Vincent’s Clinical School, UNSW Sydney, Randwick, NSW, Australia

Abstract

Since the emergence of the COVID-19 pandemic in early 2020, a key challenge has been to define risk factors, other than age and pre-existing comorbidities, that predispose some people to severe disease, while many other SARS-CoV-2-infected individuals experience mild, if any, consequences. One explanation for intra-individual differences in susceptibility to severe COVID-19 may be that a growing percentage of otherwise healthy people have a pre-existing asymptomatic primary immunodeficiency (PID) that is unmasked by SARS-CoV-2 infection. Germline genetic defects have been identified in individuals with life-threatening COVID-19 that compromise local type I interferon (IFN)-mediated innate immune responses to SARS-CoV-2. Remarkably, these variants – which impact responses initiated through TLR3 and TLR7, as well as the response to type I IFN cytokines – may account for between 3% and 5% of severe COVID-19 in people under 70 years of age. Similarly, autoantibodies against type I IFN cytokines (IFN-α, IFN-ω) have been detected in patients’ serum prior to infection with SARS-CoV-2 and were found to cause c. 20% of severe COVID-19 in the above 70s and 20% of total COVID-19 deaths. These autoantibodies, which are more common in the elderly, neutralise type I IFNs, thereby impeding innate antiviral immunity and phenocopying an inborn error of immunity. The discovery of PIDs underlying a significant percentage of severe COVID-19 may go some way to explain disease susceptibility, may allow for the application of targeted therapies such as plasma exchange, IFN-α or IFN-β, and may facilitate better management of social distancing, vaccination and early post-exposure prophylaxis.

Keywords: COVID-19, inborn errors of immunity, interferon autoantibodies, primary immunodeficiency
INTRODUCTION

The novel coronavirus SARS-CoV-2 is the cause of COVID-19, a disease which swept the world in 2020, and has resulted in more than 250 million infections and 5 million deaths to date. The pathogenesis of severe COVID-19 may relate both to viral load and persistence, and to the effects of an excessive inflammatory response. It is not surprising therefore that there is a role for antiviral therapies such as remdesivir and molnupiravir, and passive immunity afforded by convalescent plasma and monoclonal antibodies to SARS-CoV-2, as well as for anti-inflammatory therapies such as tocilizumab in managing severe COVID-19.

A majority of SARS-CoV-2-infected people do not suffer severe disease. Despite this, several risk factors have been identified that predict severe and even fatal COVID-19, including male gender, advanced age, pre-existing heart disease, hypertension, diabetes, malignancy and obesity. However, these factors constitute only a small part of the risk, given that many elderly people have also been reported to have minimal or asymptomatic disease, whereas some young, seemingly healthy individuals can suffer significant morbidity or mortality. The inference here is that – in contrast with the last great pandemic caused by human immunodeficiency virus (HIV) – humans do not exhibit a species-level vulnerability to SARS-CoV-2, but rather some individuals manifest a risk which is far greater than the average human. To understand what might underlie this excess risk in some people, studies have assessed the role of common genetic variation in mediating risk, using technologies such as genome wide association studies (GWAS). These studies have defined a number of susceptibility loci for severe COVID-19; however, the associated relative risk of these loci is generally far too small (e.g. twofold) to uniquely explain more than a small portion of the undefined risk. Far more revealing are studies that have searched for rare or even ‘private’ genetic variation using genomic sequencing technologies. This process has been led by the COVID Human Genetic Effort (CHGE, www.covidhge.com) and has identified a range of variants in immune genes that carry an extremely high relative risk of severe disease (e.g. 50-fold). These single gene pathogenic variants explain most if not all of the individual risk in ~3–5% of patients and have effectively unmasked a previously undiagnosed primary immunodeficiency (PID) in these individuals. Additionally, the CHGE and others have discovered that a further c. 10% of cases of severe COVID-19 results from another type of previously asymptomatic PID associated with anti-cytokine autoantibodies, which may explain 20% of all COVID-19 deaths.

This review will introduce the concepts of rare defects in immune genes leading to an infectious predisposition and specifically COVID-19, which are most correctly referred to as ‘inborn errors of immunity’ (IEI), and the phenocopies of those diseases caused by anti-cytokine autoantibodies. For ease of understanding, we will use the acronym IEI to refer to genetic entities, whereas when discussing the combination of the two groups, we will preference the term PID.

INBORN ERRORS OF IMMUNITY

Inborn errors of immunity are rare germline defects in single genes that predispose an individual to a severe – and often fatal – immune disease, such as recurrent or opportunistic infection, autoimmunity, autoinflammation, allergy or even malignancy. There are currently more than 450 different IEI which vary widely in their presentations. Among those IEI which predispose to infection, many of the better known entities involve a broad vulnerability to different organisms. These include defects of adaptive immunity through disrupted development of B cells or T cells in X-linked agammaglobulinaemia (XLA) or severe combined immunodeficiency (SCID), respectively, or loss of innate immune cell function, as occurs in neutrophils in chronic granulomatous disease (CGD). There are also many IEI where rather than complete loss of an entire cell function, there is dysfunction of a molecular pathway which may have evolved to mediate host defence against a subgroup of organisms. In these instances, there may be a narrow predisposition to one or a few infectious agents. Examples of the latter include genetic defects in the complement pathway that predispose to recurrent Neisseria disease, defects of the IFN-γ/IL-12 pathways that predispose to invasive infection with low pathogenicity non-tuberculous mycobacteria...
(NTM)\textsuperscript{19,20} or defects in IL-17-mediated immunity resulting in chronic mucocutaneous fungal infections.\textsuperscript{22,23} It has even been suggested that many or most humans may harbour a susceptibility to one or more of the vast array of microbes to which we may be exposed.\textsuperscript{24}

Inborn errors of immunity that predispose specifically to severe viral infection – including RNA viruses such as SARS-CoV-2 – are also well described. Defects have been identified in genes that either encode for pattern recognition receptors that bind viral RNA within cytoplasmic endosomes (e.g. TLR3 which binds double-stranded RNA, dsRNA) or are important for molecular pathways that generate an innate antiviral state in surrounding tissues following infection (e.g. IRF3, IRF7, IFNAR1, IFNAR2, STAT2, IFIH1). Mechanistically, binding of intracellular dsRNAs to Toll-like receptor 3 (TLR3) elicits a cascade leading to the production and release of type I IFNs, which in turn act on other local cells to activate antiviral gene expression and antiviral state in surrounding tissues following infection (e.g. IRF3, IRF7, IFNAR1, IFNAR2, STAT2, IFIH1). mechanisms.

Errors of Type I Interferon

PREVIOUSLY UNDIAGNOSED INBORN ERRORS OF TYPE I INTERFERON IMMUNITY IN COVID-19

To investigate the presence of rare variation underlying severe COVID-19, the CHGE (www.covidhge.com) was formed, comprising clinical teams from around the world. The group
recruited 987 patients with proven life-threatening COVID-19, two-thirds of whom were under 65 years of age, along with 663 asymptomatic or pauci-symptomatic individuals with proven COVID-19, and 1227 uninfected healthy controls.\textsuperscript{13,14} In the first study, Zhang et al.\textsuperscript{14} performed whole exome or whole genome sequencing (WGS) on severe COVID-19 patients and mild or asymptomatic SARS-CoV-2-infected individuals, with targeted analysis of the 13 known disease-associated TLR3/type I IFN genes (\textit{TLR3}, \textit{IRF3}, \textit{IRF7}, \textit{IRF9}, \textit{TBK1}, \textit{TICAM1} (TRIF), \textit{UNC93B1}, \textit{IFNAR1}, \textit{IFNAR2}, \textit{TRAF3}, \textit{STAT1}, \textit{STAT2} and \textit{IKBKG/NEMO}; Figure 1). The group of patients who were severely affected was found to have a higher number of rare genetic variants (minor allele frequency < 0.001, or less than 1:1000 alleles in the healthy population), predicted to be loss of function (pLOF; Figure 1), than did minimally affected COVID-19 patients [odds ratio (OR) = 8.28; 95% confidence interval (CI) = 1.04–65.64].\textsuperscript{14} This included two patients with biallelic LOF mutations in each of \textit{IRF7} and \textit{IFNAR1},\textsuperscript{14} which would be expected to predispose to severe viral infection with complete or near-complete penetrance,\textsuperscript{27,29} and eleven individuals carrying heterozygous LOF variants in \textit{TLR3}, \textit{TICAM1}, \textit{TBK1} and \textit{IRF3}, which have been associated with heterozygous predisposition to infection with other viruses prior to the pandemic.\textsuperscript{26,32,33} In fact, there was only a single heterozygous pLOF variant found in a single patient in the asymptomatic/mild group.\textsuperscript{14} The team then went through a complex process of validating each variant, by creating cell lines transfected with plasmids containing each of 118 different variants identified from WGS, and using an array of molecular assays to assess pathway
function. They demonstrated 24 true LOF genetic variants in eight genes – TLR3, IRF3, IRF7, TBK1, TICAM1, UNC93B1, IFNAR1 and IFNAR2 – in 23 individuals with life-threatening COVID-19, showing decreased function through the TLR3/IFN/ISG pathway, and increased *in vitro* growth of SARS-CoV-2. Overall, these rare LOF variants were calculated to account for predisposition to severe COVID-19 in 3.5% of the entire cohort SARS-CoV-2-infected individuals.

More recently, findings from another group queried the relationship between genetic defects in the TLR3/type I IFN pathway and severe COVID-19 at a population statistical level. Thus, there remains an open debate as to what proportion of severe COVID-19 results from defects in this pathway. The two studies were very different in their aims and the constitution of the cohorts. For instance, the second study by Povysil et al. not including mild or asymptomatic COVID-19-positive controls, while the composition of the CHGE including specialists in the field of inborn errors, might have resulted in an unintentional bias towards the inclusion of cases with features of possible single gene inheritance (e.g. familial occurrence or consanguinity). However, irrespective of the size of the effect, there can be little doubt that patients exist with undiagnosed genetic defects in TLR3/type I IFN pathway, and these patients are already benefitting from being identified.

Additionally, the CHGE and others have now also reported LOF variants in another IFN-related gene – TLR7 – associated with severe COVID-19. Similar to TLR3, TLR7 encodes an endosomal receptor for RNAs, but is targeted by the native single-stranded RNA (ssRNA) and has a different cellular distribution to TLR3, being expressed by B cells and certain myeloid-lineage cells, including plasmacytoid dendritic cells, which produce copious amounts of type I IFNs (Figure 1). Defects in this X-linked gene, which had not been identified as causing a PID before the pandemic, have been estimated to cause an additional 1–2% of severe cases in men, but with incomplete penetrance.

**AUTOANTIBODY-MEDIATED PHENOCOPIES OF INBORN ERRORS OF IMMUNITY**

For many years, it has been recognised that groups of HIV-negative patients may present in adult life with what might otherwise be considered as AIDS-defining opportunistic infections. An example is a group of predominately female patients living in or descending from parts of South-East Asia, presenting with invasive NTM infection, or less commonly other exotic infections including Histoplasmosis and Cryptococcosis. These individuals do not possess genetic defects in the IFNγ pathway, but rather produce autoantibodies against IFNγ or IL-12 itself, thereby interrupting this pathway and the signals that innate and adaptive immune cells provide to monocytes that allow them to clear infection. Other examples of anti-cytokine antibodies predisposing to infection include the following: anti-IL-6 causing recurrent staphylococcal infection, a single report of anti-type I IFN autoantibody-associated chickenpox and a range of anti-cytokine antibodies to IL-12, IL-17, IL-1 and type I interferons in patients with thymic neoplasia.

One of the most informative but rare examples of infectious diseases associated with anti-cytokine autoantibodies comes from the IEI due to inactivating mutations in *AIRE* resulting in APECED, which – consistent with the role of AIRE in self-tolerance – is associated with a powerful predisposition to autoimmunity. Mucosal candidiasis in these patients is attributed to neutralising autoantibodies that block the function of IL-17 and IL-22. Strikingly, it has been well established that autoantibodies against type I IFNs were almost ubiquitous in this disease, and recently, these antibodies have been associated with susceptibility to severe herpesvirus infections. Thus, when APECED patients began to be identified with severe COVID-19, including 86% of infected patients requiring hospitalisation in one study, one inference was that predisposition to life-threatening SARS-CoV-2 infection might be autoantibody mediated and that the candidate pathogenic autoantibodies might target type I IFNs.

**AUTOANTIBodies TO TYPE I INTERFERONS IN COVID-19**

The same groups of relatively younger COVID-19 patients who underwent WGS by the CHGE were subsequently assessed for the presence of autoantibodies to type I IFNs (IFN-α, IFN-β and IFN-ω). A total of 101/987 (10.2%) of severe COVID-19 patients were found to have...
autoantibodies against type I IFNs, versus 0/663 (0%) of those with minimal disease. These autoantibodies are extremely effective at neutralising type I IFN cytokines, thereby facilitating SARS-CoV-2 infection of cell lines in vitro, appearing more powerful in this respect than a monoclonal antibody designed for exactly that purpose. While patients with COVID-19 generally demonstrate low levels of IFN-stimulatory genes, this has been found to be particularly evident in dendritic cells isolated from individuals with critical disease who have autoantibodies against type I IFNs.67 These patients were on average, older than the median age of the cohort,13 while 95/101 (94%) were male.67 More recently, the CHGE reported on these autoantibodies in a cohort of older patients, demonstrating an increasing prevalence associated with age (specifically against IFN-α and IFN-ω) and disease severity, rising to 21% of severe cases in > 80 year olds, and about 20% of fatal COVID-19.67 The increasing prevalence of autoantibodies in older patients with severe disease mirrors an increase in these autoantibodies in the healthy uninfected population, being present in approximately 4% of healthy individuals aged > 70 years old.67 These findings are now being reproduced by other investigators in other cohorts.5,67–71

IMPLICATIONS OF RARE DEFECTS IN TYPE I INTERFERONS FOR THE TREATMENT OF SEVERE COVID-19

Moving forward, the identification of PIDs underlying severe COVID-19 has significant implications for therapy. Patients with genetic defects that cripple production of type I IFNs, but have intact functioning IFN-αR1/IFN-αR2 heterodimer, may benefit from cytokine supplementation with exogenous IFN-α or IFN-β (may even work for patients with autoantibodies),67 which are approved for the treatment of hepatitis B,72 hepatitis C73 and multiple sclerosis.74 Patients with autoantibodies against type I IFNs may also be responsive to removal of these antibodies by plasma exchange,75 and this will include many patients with APECED who have an exceptionally high rate of severe COVID-19 due to these autoantibodies.46 Additionally, the presence of high titre autoantibodies in plasma of a low proportion of patients who have recovered from COVID-19 may explain why convalescent plasma is a less effective treatment for COVID-19 than might otherwise have been expected.76

WHERE TO LOOK FOR OTHER RARE IMMUNE DEFECTS IMPACTING COVID-19 SEVERITY

Further PIDs underlying severe COVID-19 may well also be associated with the type I IFN response, which has been found to be defective in most patients with or without autoantibodies.67 The viral sensing genes OAS1/2/3 and the signalling molecule TYK2 which are integral components of the type I IFN signalling pathway77 have been identified as susceptibility loci in GWAS.10 Additionally, direct sequencing of two genes coding for the interferon lambda cytokine, IFNL3 and IFNL4, has been associated with severe disease.78 Data from GWAS are now pointing towards monocyte and macrophage cell homing molecules such as chemokines and chemokine receptors, as potentially increasing susceptibility to severe disease.79,80 However, further entities may not be identified quickly, given that prior to the pandemic, it was difficult to identify more than 50% of gene defects underlying presumed monogenic PIDs.81 Low identification rates can reflect pathogenic variants in non-coding regions of known genes that require different sequencing technologies to identify them,82 or variants in novel genes which, because of their rarity, do not give a statistical signal even within large populations, and where the process of proving pathogenesis through molecular modelling may take years.83

There are two main strategies being employed to identify additional genes where rare variation may underlie undiagnosed PIDs in COVID-19 patients. The first is the example of the CGHE, comparing the complete genomic sequence of individuals with severe disease versus those with mild or asymptomatic infection. This optimal technique has the capacity to identify variants in known disease-associated genes,14 but also novel genes such as TLR7.54

The second strategy is to focus on sequencing candidate genetic regions identified by GWAS. This approach can be successful because, even though the low relative risk of variants associated with GWAS informs little about why a given patient suffered bad disease,84 the signal from the GWAS may actually reflect much rarer variants.
carrying a far greater risk and relevance, travelling in linkage disequilibrium with the common variant identified in the GWAS. This strategy has revealed rare variants in CCR5 in severe COVID-19 patients, although further molecular validation of this latter association is needed before it can be added to the list of COVID-19-predisposing gene defects.

Finally, as mentioned at the outset, not all of the consequences of COVID-19 relate to viral persistence, with some directly attributable to inflammation, in particular multisystem inflammatory syndrome in children (MIS-C). It is possible that this entity may also have a genetic underpinning, with cases of MIS-C now reported as associated with LOF variants in the regulator gene SOCS1, which was itself only recently identified as an IEI. Interestingly, SOCS1 functions to inhibit JAK/STAT signalling, including blocking TYK2-mediated signalling through the type I interferon receptor, suggesting that excessive type I IFN activity may play a role in pathogenesis of MIS-C (Figure 1).

A DIFFERENT TYPE OF PANDEMIC PREDISPOSITION?

The last great pandemic to impact humanity was different from COVID-19, in that humans as a species are mostly susceptible to HIV. On the one hand, had we been unable to limit the spread of HIV, that epidemic would have exerted a huge pressure on our species, selecting exclusively for those rare individuals who by serendipity are resistant to the virus, such as those who carry the CCR5-Δ32 variant. On the other hand, with COVID-19 as with pandemic influenza, the majority of the population do not suffer major deleterious infection, with only a small percentage being more severely impacted. For influenza, individual susceptibility is only recently beginning to be understood; however, we now have an explanation for susceptibility to COVID-19 in 15–20% of individuals who suffer severe disease, with the virus seeming less likely to affect the average humans, or even humans with common variation, but rather those with rare, highly deleterious, genetic or immune variation. In effect, we as a species appear to have reasonable innate resistance to the effects of SARS-CoV-2, presumably because of previously having had our genomes put under pressure by similar viruses, resulting in the evolution of a protective type I IFN response among other features of innate immunity. Exceptions to this are individuals with anti-cytokine autoantibodies, and those with deleterious rare germline variants, who in the brutal language of evolutionary biology, are being put under the pressure of ‘purifying selection’.

The finding of undiagnosed PIDs underlying severe COVID-19 was not arrived at in isolation, but was made possible because of an accumulated knowledge gained from decades of studying rare IEI. That work has included slowly unpicking the genetics of predisposition to a range of other infections including HSV encephalitis, influenza, candida, EBV and NTM. These studies have rarely involved large cohorts, probably because, by contrast to COVID-19, for rare variants that predispose to these organisms, humans have been experiencing a purifying pressure for many generations. Nonetheless, over time IEI are beginning to account for a very significant percentage of people with globally important diseases, including the recent identification of the P1104A variant in TYK2 underlying tuberculosis in 1% of cases in people of European ancestry. It is therefore unsurprising that members of the CHGE have been passionate advocates for the value of well-supported evidence deriving from humans with such genetic predispositions, even when those data come from a single individual.

CONCLUSION

Rare genetic and immune variation resulting in previously undiagnosed PID has been identified as the cause of COVID-19 in c. 15% of individuals who suffer severe disease, increasing to c. 20% in the elderly, and in fatal disease. Given the slow process of proving these associations, the extent of this pathogenic variation is likely to increase with time and is already the most significant scientific contribution thus far to understanding what makes one person more susceptible to SARS-CoV-2 than another. It highlights a group of apparently healthy individuals with defective immunity, who constitute a greater priority for the generation of protection through social distancing and vaccination, as well as potentially benefiting from targeted therapies.

These findings, which have so far largely derived from the work of the CHGE but are now...
being verified by other groups, may change the way we think about infectious predisposition. It seems that other than for completely novel infections such as HIV where there is a species-level vulnerability, the study of rare or novel defects constituting a high level of infectious risk in an individual or individuals who possess them, may prove to be of more benefit for identifying factors that really impact predisposition to severe infection within populations, than averaging vastly smaller predispositions across large groups. It seems that with regard to fighting infection, humans are not so much a whole, as the sum of our parts.

**AUTHOR CONTRIBUTIONS**

Paul Edgar Gray: Conceptualization; Writing – original draft; Writing – review & editing. Adam W Bartlett: Conceptualization; Writing – review & editing. Stuart G Tangye: Conceptualization; Writing – review & editing.

**CONFLICT OF INTEREST**

The authors declare no conflicts of interest.

**REFERENCES**

1. Mehta P, McCauley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.
2. Holman W, Holman W, McIntosh S et al. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials 2021; 22: 561.
3. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest 2021; 131: e152740.
4. Korper S, Weiss M, Zickler D et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest 2021; 131: e152264.
5. Arnold Egloff SA, Junglen A, Restivo JS et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Invest 2021; 131: e151788.
6. Eckhardt CM, Cummings MJ, Rajagopalan KN et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials 2020; 21: 499.
7. Group RC, Horby P, Lim WS et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693–704.
8. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–1645.
9. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.
10. Pairo-Castineira E, Clohisey S, Klaric L et al. Genetic mechanisms of critical illness in Covid-19. Nature 2021; 591: 92–98.
11. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 2021; 600: 472–477.
12. Fricke-Galindo I, Falfan-Valencia R. Genetics insight for COVID-19 susceptibility and severity: a review. Front Immunol 2021; 12: 622176.
13. Bastard P, Rosen LB, Zhang Q et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: eabd4585.
14. Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370: eabd4570.
15. Fallerini C, Daga S, Mantovani S et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. Elife 2021; 10: e67569.
16. Bastard P, Gervais A, Le Voyer T et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 2021; 6: e67569.
17. Zhang Q, Cobat A, Bastard P et al. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. J Clin Invest 2021; 131: e152474.
18. Ku CL, Chi CY, von Bernuth H, Doffinger R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum Genet 2020; 139: 783–794.
19. Boussifah A, Jeddane L, Picard C et al. Human inborn errors of immunity: 2019 update of the IUIS PHENOTYPICAL CLASSification. J Clin Immunol 2020; 40: 66–81.
20. Tangye SG, Al-Herz W, Boussifah A et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol 2020; 40: 24–64.
21. Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence 2014; 5: 98–126.
22. Puel A, Cypowyj S, Marodi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12: 616–622.
23. Cypowyj S, Picard C, Marodi L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol 2012; 42: 2246–2254.
24. Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science 2007; 317: 617–619.
25. Zhang SY, Abel L, Casanova JL. Mendelian predisposition to herpes simplex encephalitis. Handb Clin Neurol 2013; 112: 1091–1097.
26. Lim HK, Huang SXL, Chen J et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency. J Exp Med 2019; 216: 2038–2056.
27. Ciancanelli MJ, Huang SX, Luthra P et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 2015; 348: 448–453.
Undiagnosed primary immunodeficiency in COVID-19

28. Asgari S, Schlapbach LJ, Anchisi S et al. Severe viral respiratory infections in children with IFIH1 loss-of-function mutations. Proc Natl Acad Sci USA 2017; 114: 8342–8347.

29. Hernandez N, Buccioni G, Moens L et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med 2019; 216: 2057–2070.

30. Hambleton S, Goodbourn S, Young DF et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci USA 2013; 110: 3053–3058.

31. Dupuis S, Dargemont C, Fieschi C et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293: 300–303.

32. Sancho-Shimizu V, Perez de Diego R, Lorenzo L et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 2011; 121: 4889–4902.

33. Herman M, Ciancanelli M, Ou YH et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med 2012; 209: 1567–1582.

34. Duncan CJ, Mohamad SM, Young DF et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med 2015; 7: 307ra154.

35. Perez de Diego R, Sancho-Shimizu V, Lorenzo L et al. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 2010; 33: 400–411.

36. Bravo Garcia-Morato M, Calvo Apalategi A, Bravo-Gallego LY et al. Impaired control of multiple viral infections in a family with complete IRF9 deficiency. J Allergy Clin Immunol 2019; 144: 309–312.e10.

37. Wack A. Monocyte and dendritic cell defects in COVID-19. Nat Cell Biol 2021; 23: 445–447.

38. Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog 2020; 16: e1008377.

39. Li Y, Renner DM, Comar CE et al. SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes. Proc Natl Acad Sci USA 2021; 118: e2022643118.

40. Hadjadi J, Yatim N, Barnabei L et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020; 369: 718–724.

41. Marcus N, Frizinsky S, Hagin D et al. Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel. Front Immunol 2020; 11: 614086.

42. Meyts I, Buccioni G, Quinti I et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol 2021; 147: 520–531.

43. Emes D, Huis A, Baumer N et al. COVID-19 in children with Down syndrome: data from the trisomy 21 research society survey. J Clin Med 2021; 10: 5125.

44. De Toma I, Dierssen M. Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19. Sci Rep 2021; 11: 1930.

45. Tangye S, Buccioni G, Meyts I. Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity. Curr Opin Allergy Clin Immunol 2021; 21: 515–524.

46. Bastard P, Orlova E, Sozaeva L et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med 2021; 218: e20210554.

47. Milito C, Lougaris V, Giardino G et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Allergy Clin Immunol Pract 2021; 9: 2904–2906.e2.

48. Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O’Parrill-Romanillos PM et al. COVID-19 in the context of inborn errors of immunity: a case series of 31 patients from Mexico. J Clin Immunol 2021; 41: 1463–1478.

49. Delavari S, Abohl hassani H, Abolnezhadian F et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J Clin Immunol 2021; 41: 345–355.

50. Poyvis G, Butler-Laporte G, Shang N et al. Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. J Clin Invest 2021; 131: e147834.

51. Poyvis G, Butler-Laporte G, Gharavi AG, Richards JB, Goldstein DB, Kiryluk K. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. Reply. J Clin Invest 2021; 131: e152475.

52. Levy R, Bastard P, Lanternier F, Lecuit M, Zhang Y, Casanova JL. IFN-alpha2a therapy in two patients with inborn errors of TLR3 and IRF3 infected with SARS-CoV-2. J Clin Immunol 2021; 41: 26–27.

53. Solarich X, Vargas-Parra G, van der Made CI et al. Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. Front Immunol 2021; 12: 791115.

54. Asano T, Boisson B, Onodi F et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 2021; 6: eabj4348.

55. van der Made CI, Simons A, van der Made CI et al. Presence of genetic variants among young men with severe COVID-19. JAMA 2020; 324: 663–673.

56. Angkasekwinai N, Suputtamongkol Y, Phoompuang P et al. Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies. PLoS One 2019; 14: e0215581.

57. O’Connell E, Rosen LB, LaRue RW et al. The first US domestic report of disseminated Mycobacterium avium complex and anti-interferon-γ autoantibodies. J Clin Immunol 2014; 34: 928–932.

58. Puel A, Picard C, Lorrot M et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 2008; 180: 647–654.

59. Pozzetto B, Mogensen KE, Tovey MG, Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis 1984; 150: 707–713.
60. Burbelo PD, Browne SK, Sampaio EP et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010; 116: 4848–4858.

61. Ferre EM, Rose SR, Rosenzweig SD et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 2016; 1: e88782.

62. Sarkadi AK, Tasko S, Csorba G, Toth B, Erdos M, Marodi L. Autoantibodies to IL-17A may be correlated with the severity of mucocutaneous candidiasis in APECED patients. J Clin Immunol 2014; 34: 181–193.

63. van der Wijst MGP, Vazquez SE, Hartoularos GC et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010; 207: 291–297.

64. Zhang L, Barker JM, Babu S et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol 2007; 125: 131–137.

65. Hetemaki I, Laakso S, Valimaa H et al. Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin Immunol 2021; 231: 108851.

66. Beccuti G, Ghizzoni L, Cambria V et al. A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor. J Endocrinol Invest 2020; 43: 1175–1177.

67. van der Wijst MGP, Vazquez SE, Hartoularos GC et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med 2021; 13: eabh2624.

68. Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D, with the Amsterdam UMCC-BI. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med 2021; 47: 704–706.

69. Abers MS, Rosen LB, Delmonte OM et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol 2021; 99: 917–921.

70. Solanich X, Rigo-Bonnin R, Gumucio VD et al. Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. J Clin Immunol 2021; 41: 1733–1744.

71. Goncalves D, Mezidi M, Bastard P et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunol 2021; 10: e1327.

72. Woo ASJ, Kwok R, Ahmed T. Alpha-interferon treatment in hepatitis B. Ann Transl Med 2017; 5: 159.

73. Al Karawi MA, Ahmed AM, Yousuf M, Shariq S, Mohamed AE, Al-Jumah A. Alpha interferon in treatment of chronic hepatitis C viral infection (CHCV): pilot study of 18 patients. Ann Saudi Med 1994; 14: 464–466.

74. Heidenreich F. Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the ‘old’ therapies? J Neurol Neurosurg Psychiatry 2015; 86: 1171.

75. de Prost N, Bastard P, Arrestier R et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. J Clin Immunol 2021; 41: 536–544.

76. Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol 2021; 93: 1111–1118.

77. Prchal-Murphy M, Semper C, Lassnig C et al. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One 2012; 7: e39141.

78. Rahimi P, Tarharoudi R, Rahimpour A et al. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J 2021; 18: 221.

79. Stikker B, Stik G, Hendriks RW, Stadhouders R. Severe COVID-19 associated variants linked to chemokine receptor gene control in monocytes and macrophages. bioRxiv 2021. https://doi.org/10.1101/2021.01.22.427813

80. Cantalupo BB, Marshall JL, Tukiainen T et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med 2017; 9: eaal5209.

81. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in primary immunodeficiencies. J Exp Med 2014; 211: 2137–2149.

82. Zhang Q, Bastard P, Bolze A et al. Life-threatening COVID-19: defective interferons unleash excessive inflammatory. Med (NY) 2020; 1: 14–20.

83. Lee PY, Platt CD, Weeks S et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol 2020; 146: 1194–1200.e1.

84. Hadjadj J, Castro CN, Tusseau M et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun 2020; 11: 5341.

85. Liu NPD, Laktushshin A, Lucet IS et al. The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun 2018; 9: 1558.

86. Pigasiris RA, De Weerd NA, Gould JA et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 2011; 286: 33811–33818.

87. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol 2005; 3: e339.

88. Ziegler JB, Lee CH, Van der Weyden MB, Bagnara AS, Beveridge J. Severe combined immunodeficiency and adenosine deaminase deficiency: failure of enzyme replacement therapy. Arch Dis Child 1980; 55: 452–457.
91. Quintana-Murci L. Understanding rare and common diseases in the context of human evolution. Genome Biol 2016; 17: 225.

92. Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332: 65–68.

93. Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr Opin Immunol 2010; 22: 467–474.

94. Liu L, Okada S, Kong XF et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208: 1635–1648.

95. Tangye SG. Genetic susceptibility to EBV infection: insights from inborn errors of immunity. Hum Genet 2020; 139: 885–901.

96. Tangye SG, Latour S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood 2020; 135: 644–655.

97. Okada S, Markle JG, Deenick EK et al. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015; 349: 606–613.

98. Kong XF, Vogt G, Itan Y et al. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Hum Mol Genet 2013; 22: 769–781.

99. Bogunovic D, Byun M, Durfee LA et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 2012; 337: 1684–1688.

100. Grant AV, Boisson-Dupuis S, Herquelot E et al. Accounting for genetic heterogeneity in homozygosity mapping: application to Mendelian susceptibility to mycobacterial disease. J Med Genet 2011; 48: 567–571.

101. Kerner G, Laval G, Patin E et al. Human ancient DNA analyses reveal the high burden of tuberculosis in Europeans over the last 2,000 years. Am J Hum Genet 2021; 108: 517–524.

102. Kerner G, Ramirez-Alejo N, Seeleuthner Y et al. Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry. Proc Natl Acad Sci USA 2019; 116: 10430–10434.

103. Vazquez SE, Bastard P, Kelly K et al. Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma. J Clin Immunol 2021; 41: 1169–1171.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.